Birthrites: Healing After Caesarean.

Genital Herpes in Pregnancy

By Nicette Jukelevics.

Genital herpes is a contagious, manageable, but incurable viral infection. Thirty million Americans are currently affected. According to the National Institutes of Health (NIH) an estimated one-fourth of pregnant women have been affected by genital herpes. Women who develop a first episode of genital herpes during pregnancy are at higher risk for miscarriage, premature rapture of the membranes and premature delivery.

Genital herpes is caused by the herpes simplex virus (HSV). Two types of HSV are recognized, both of which can cause genital herpes symptoms. Type I (HSV-1) oral herpes commonly causes cold sores or fever blisters. Type 2 (HSV-2) is the kind that most often causes genital sores.

The CDC estimates that between 200,000 and 500,000 Americans experience a primary episode of genital herpes each year. Most genital herpes infections are acquired directly by sexual contact with a partner who has active sores in the genital area. A person with oral herpes can transmit the infection to the genital area of a partner during oral-genital sex. HSV can be transmitted by someone who is asymptomatic and may not be aware of the infection. The majority of people who become infected with HSV never develop any symptoms. When symptoms do occur, they vary widely. After exposure to the virus, symptoms begin to appear within two to 20 days, and can last for weeks.

Recurrent Outbreaks of HSV

After the initial outbreak, the virus can remain inactive inside nerve cells at the end of the spinal cord and reactivate from time to time. Many people infected with genital herpes have about five to eight outbreaks a year. However, not everyone has recurrent symptoms. The number of outbreaks will decrease over time, and when they do occur, fewer sores are present. They tend to heal faster and be less painful. Although recurrent outbreaks cannot be predicted, they tend to occur when the body's immune system is taxed by illness or fatigue, during menstruation, or by sexual intercourse.

Neonatal Herpes

Although 20-25% of pregnant women have genital herpes, less than 0.1% of newborns become infected. Although neonatal herpes is rare, newborns who become infected are at risk for major complications and damage to the central nervous system. HSV can cause eye, mouth or throat infections. The CDC estimates that 75% to 90% of newborns with HSV suffer severe long term complications. Without treatment up to 65% of infected newborns die.

The majority of newborns become infected by exposure to the virus present in the birth canal. Occasionally the virus is transmitted in utero. Less common is the possibility of the baby becoming infected from lesions on the mother's nipple during breast feeding or from a father with a cold sore.

Women who were infected with the virus before they became pregnant and do not have a recurrent episode during pregnancy have a very small chance of transmitting it to their babies. They have developed antibodies that are passed on to the fetus through the placenta.

According to the National Institute of Allergy and Infectious Diseases (NIAID) with a first outbreak of genital herpes that develops near the time of delivery the baby's risk of infection is one in three. With a recurrent outbreak the risk is less than one in 30.

Reducing the Risk of Neonatal Herpes

Testing an expectant mother for HSV antibodies can alert her care provider that she may be at risk for a recurrence during her pregnancy. However, the CDC cautions that a positive test result in an asymptomatic pregnant woman is not a valuable predictor of the risk of transmission, and states "in the absence of lesions during the third trimester, routine serial cultures for herpes simplex virus (HSV) are not indicated for women who have a history of recurrent genital herpes. However, obtaining cultures from such women at the time of delivery may be useful in guiding neonatal management." (NfMWR 1998;47(No.R_R-1)

When pregnant women have active HSV lesions, the use of anti-viral drugs is currently recommended as the best alternative for lowering the risk of neonatal herpes. Treating the expectant mother with anti-viral drugs decreases the frequency of lesion outbreaks and may decrease the risk of neonatal exposure. Three drugs approved by the Food and Drug Administration are acyclovir (Zovirax or Avirax), famciclovir (Famvir), and valacyclovir (Valtrex).

According to the CDC's current Guidelines for Treatment of Sexuaffy Transmitted Disease (1998) "prophylactic cesarean section is not indicated for women who do not have active genital lesions at the time of delivery." When no lesions are observed, the American Social Health Association recommends avoiding the use of amniotomy, fetal scalp electrodes, and vacuum extractors or forceps to reduce the risk of neonatal infection.

Many physicians still recommend a cesarean birth for a woman with a history of genital herpes despite the fact that she may not have any clinical symptoms at the time of delivery. This approach is based on the understanding that women may be asymptomatic but still shed the virus at the time of delivery. However, researchers at the University of San Francisco suggest that prophylactic use of acyclovir in the third trimester for women with recurrent genital herpes may lower the risk of HSV transmission to their infants and reduce unnecessary cesareans (Randolph et al, 1996).

The safety of systemic acyclovir and valacyclovir therapy in pregnant women has not been established. The CDC maintains a registry to assess their use and effects. Although the numbers reported have not reached statistical significance, there have been no indications of adverse affects of anti-viral therapy during pregnancy to date. Acyclovir is used to treat newborns infected with HSV.

Emotional Aspects of Genital Herpes

Although the physical aspects of an active episode of genital herpes can be successfully treated, its emotional impact on a pregnant woman is more complex. Women's reactions vary and may include feelings of anxiety, grief, and a negative self-image. Women may feel isolated, lonely, or angry. They may feel guilty for the possibility of transmitting the virus to their infants. Fears about future fertility are also common.

Women who acquired genital herpes before becoming pregnant may worry about the risk of an active recurrence and the possibility of a cesarean birth. Some women may need to be referred for supportive therapy (Wooley 1997).

Although genital herpes is very rarely a serious health problem, it can have a serious physical and emotional impact on a pregnant woman and her partner. Neonatal herpes may be rare, but it can be devastating for the family. Acknowledging that genital herpes does affect about 25% of pregnant women and referring the parents to the wide range of educational and support resources available in the community will enhance their emotional well being and help them to best prepare for the birth of their child.

*Nicette Jukelevics, MA, XCE, a DONA-trained doula, has been teaching expectant parents for twenty years She is a published author and speaker on VBAC and cesarean issues. Nicette co-authored with Ruth Ancheta The VBAC Source Book and Teaching Kit, soon to be published by ICEA.
A longer version of this article appeared in Childbirth Instructor, Jan/Feb 1999.

References:

  • American Social Health Association. Herpes Simplex and Pregnancy. 1997.
  • National Institute of Allergy and Infections Diseases. Genital Herpes Fact Sheet. 1997. Retrieved online from www.niaid.nih.gov/factsheets/stdherp.htm.
  • National Institutes of Health, Center for Disease Control and Prevention. Guidelines for Treatment of Sexually Transmitted Diseases 1998. MMWR 1998, 47(no. RR- 1).
  • Randolph AG et al. Acyclovir prophylaxis in late pregnancy to prevent neonatal herpes: a cost-effectiveness analysis. Obstet Gynecol 1996. 88(4 Pt 1):603-6 10.
  • Wooley, Paul. Genital Herpes: Treatment Guidelines. 1997. Published online by Medscape Women's Health 2(5):1-10.

Resources
Education and Prevention

American Foundation for the Prevention of

Venereal Disease, Inc.

700 Broadway, Suite 638

New York, NY 10003

(212) 759-2069

Herpes Resource Center

American Social Health Association

PO Box 13827

Research Triangle Park, NC 27709-9940